Notícias

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

In April 2026, Intuitive Surgical voluntarily initiated an ongoing Class II worldwide recall of certain da Vinci surgical system components after discovering an E-brake retainer pin issue that could impede emergency braking or cause uncontrolled column motion, with 454 affected units identified by specific serial numbers. This safety action, alongside growing attention on Intuitive’s AI-enabled da Vinci 5 rollout and competitive pressures in robotic surgery, raises fresh questions about how...

Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.

Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 9, 2026, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical, Inc. (NASDAQ:ISRG) with an Outperform rating and $518 price target. Chopra said the da Vinci 5 upgrade cycle remains in the early innings, procedure growth […]

The robotic surgery company has posted earnings beats in its past four quarters. Can it make it five in a row?

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

And Goldman Sachs may be right.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting results this Thursday afternoon. Here’s what investors should know.

Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.

Intuitive Surgical's stock has fallen sharply in 2026, but that is more a function of investor sentiment than of the company.

Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.

Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.

Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.

This is a product-cycle year for Intuitive Surgical. The company's growth is fueled by hospitals and surgeons adopting its new da Vinci 5 and existing Ion robotic systems.

ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.

Intuitive Surgical (NASDAQ:ISRG) looks compelling ahead of its July 16 earnings report, and the setup rarely gets this clean for a category leader trading well below fair value. Shares sit at $413.58, down 26.71% YTD, while the 247 base-case target of $559.79 implies 35.35% upside. Wall Street sits higher still at $563.35, with 22 buy ... Intuitive Surgical Has +35% Upside: A Compelling Buy Story Before July 16

Intuitive Surgical stock has returned 28.4% over the past five years, yet its current checks point to a company that is not clearly cheap, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model sitting close to the market price while earnings based multiples lean expensive. Over five years, a 28.4% share price gain suggests Intuitive Surgical has rewarded patient holders, even though shorter term returns have been weaker. Growth expectations tied to expanding robotic...

Intuitive Surgical (ISRG) is in focus after voluntarily recalling certain Da Vinci surgical system components tied to a potential E-brake pin issue. This development is prompting fresh attention on product risk and how it might factor into the stock. See our latest analysis for Intuitive Surgical. Against this backdrop, Intuitive Surgical’s short term share price momentum has softened, with the stock down 4.5% over the past week and 9.7% over the past 90 days. However, the 3 year total...

Intuitive Surgical, Inc. (ISRG) closed at $406.78 in the latest trading session, marking a -1.16% move from the prior day.

ISRG is set to report Q2 results on July 16, with sales and EPS expected to rise, while investors weigh margin pressure against strong adoption of da Vinci 5.

Intuitive Surgical Inc. (NASDAQ:ISRG) is one of the 10 Best AI Stocks to Watch in July. On July 6, Evercore ISI lowered its target price for Intuitive Surgical Inc. (NASDAQ:ISRG) to $430 from $480 and kept an In Line rating on the stock. The firm’s Q2 preview for MedTech, Life Sciences Tools, and Diagnostics shows […]

The Japanese medical robotics company, a joint venture between Kawasaki and Sysmex, is preparing for a European launch after expanding in the Asia-Pacific region.

The options market has priced a sizable range of outcomes for the surgical robotics leader, and if you hold the shares, you are already carrying that full exposure.

Pre-Market Stock Futures: Futures are trading mixed after another tough day across Wall Street, with all the major indices crushed early on, before the Nasdaq made a late-afternoon push to wind up just modestly higher at 25,870, up 0.20%. The S&P 500 also rallied in the afternoon, erasing a big deficit, to finish the session ... Here Are Thursday’s Best Wall Street Analyst Research Calls: Align Technology, American Tower, Caesars Entertainment, Cohu, Five Below, Intuitive Surgical, Salesforce, T

If you hold shares in this surgical robotics leader, you are already carrying a sizable two-sided risk, whether you trade options or not.

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.